+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biosimilar Interleukins Global Market Report 2021: COVID-19 Growth and Change to 2030

  • ID: 5446201
  • Report
  • September 2021
  • Region: Global
  • 175 Pages
  • The Business Research Company

FEATURED COMPANIES

  • Bio-Thera Solutions
  • Gedeon Richter
  • MabPharm
Biosimilar Interleukins Global Market Report 2021: COVID-19 Growth and Change to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global biosimilar interleukins market.







This report focuses on the biosimilar interleukins market which is experiencing strong growth. The report gives a guide to the biosimilar interleukins market which will be shaping and changing our lives over the next ten years and beyond, including the market's response to the challenge of the global pandemic.

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for biosimilar interleukins? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Biosimilar Interleukins market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider biosimilar interleukins market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The biosimilar interleukins market section of the report gives context. It compares the biosimilar interleukins market with other segments of the biosimilar interleukins market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, biosimilar interleukins indicators comparison.

Scope


Markets Covered:


  • By Type: IL-17; IL-23; IL-1; IL-5; IL-6
  • By Application: Psoriasis; Psoriatic Arthritis; Rheumatoid Arthritis; Asthma; Inflammatory Bowel Disease (IBD); Others
  • By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies; Clinics; Research Institutes

Companies Mentioned:


MabPharm; Gedeon Richter; Bio-Thera Solutions; Sorrento Therapeutics/MabTech; Sunshine Guojian Pharmaceutical

Countries:


Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions:


Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series:


Five years historic and ten years forecast.

Data:


Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data segmentations:


Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing:


Data and analysis throughout the report is sourced using end notes.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Biosimilar Interleukins Market

What is the estimated value of the Global Biosimilar Interleukins Market?

The Global Biosimilar Interleukins Market was estimated to be valued at $1.3 billion in 2021.

What is the growth rate of the Global Biosimilar Interleukins Market?

The growth rate of the Global Biosimilar Interleukins Market is 38.8%, with an estimated value of $4.9 billion by 2025.

What is the forecasted size of the Global Biosimilar Interleukins Market?

The Global Biosimilar Interleukins Market is estimated to be worth $4.9 billion by 2025.

Who are the key companies in the Global Biosimilar Interleukins Market?

Key companies in the Global Biosimilar Interleukins Market include MabPharm, Gedeon Richter, Bio, Thera Solutions and Sunshine Guojian Pharmaceutical.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bio-Thera Solutions
  • Gedeon Richter
  • MabPharm

1. Executive Summary2. Biosimilar Interleukins Market Characteristics3. Biosimilar Interleukins Market Trends and Strategies4. Impact Of COVID-19 On Biosimilar Interleukins
5. Biosimilar Interleukins Market Size and Growth
5.1. Global Biosimilar Interleukins Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global Biosimilar Interleukins Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market
6. Biosimilar Interleukins Market Segmentation
6.1. Global Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • IL-17
  • IL-23
  • IL-1
  • IL-5
  • IL-6
  • Others
6.2. Global Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Asthma
  • Inflammatory Bowel Disease (IBD)
  • Others
6.3. Global Biosimilar Interleukins Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Clinics
  • Research Institutes

7. Biosimilar Interleukins Market Regional and Country Analysis
7.1. Global Biosimilar Interleukins Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Biosimilar Interleukins Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8. Asia-Pacific Biosimilar Interleukins Market
8.1. Asia-Pacific Biosimilar Interleukins Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
9. China Biosimilar Interleukins Market
9.1. China Biosimilar Interleukins Market Overview
9.2. China Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
10. India Biosimilar Interleukins Market
10.1. India Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11. Japan Biosimilar Interleukins Market
11.1. Japan Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12. Australia Biosimilar Interleukins Market
12.1. Australia Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13. Indonesia Biosimilar Interleukins Market
13.1. Indonesia Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14. South Korea Biosimilar Interleukins Market
14.1. South Korea Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15. Western Europe Biosimilar Interleukins Market
15.1. Western Europe Biosimilar Interleukins Market Overview
15.2. Western Europe Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16. UK Biosimilar Interleukins Market
16.1. UK Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17. Germany Biosimilar Interleukins Market
17.1. Germany Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18. France Biosimilar Interleukins Market
18.4. France Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.5. France Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19. Eastern Europe Biosimilar Interleukins Market
19.1. Eastern Europe Biosimilar Interleukins Market Overview
19.2. Eastern Europe Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20. Russia Biosimilar Interleukins Market
20.1. Russia Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21. North America Biosimilar Interleukins Market
21.1. North America Biosimilar Interleukins Market Overview
21.2. North America Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22. USA Biosimilar Interleukins Market
22.1. USA Biosimilar Interleukins Market Overview
22.2. USA Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23. South America Biosimilar Interleukins Market
23.1. South America Biosimilar Interleukins Market Overview
23.2. South America Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24. Brazil Biosimilar Interleukins Market
24.1. Brazil Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25. Middle East Biosimilar Interleukins Market
25.1. Middle East Biosimilar Interleukins Market Overview
25.2. Middle East Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26. Africa Biosimilar Interleukins Market
26.1. Africa Biosimilar Interleukins Market Overview
26.2. Africa Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
27. Biosimilar Interleukins Market Competitive Landscape and Company Profiles
27.1. Biosimilar Interleukins Market Competitive Landscape
27.2. Biosimilar Interleukins Market Company Profiles
27.2.1. Novartis AG
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. AbbVie Inc.
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Eli Lilly and Company
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Regeneron Pharmaceuticals, Inc
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. AstraZeneca
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Biosimilar Interleukins Pipeline Analysis29. Key Mergers and Acquisitions in the Biosimilar Interleukins Market30. Biosimilar Interleukins Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright and Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bio-Thera Solutions
  • Gedeon Richter
  • MabPharm
Major players in the biosimilar interleukins market are MabPharm, Gedeon Richter, Bio-Thera Solutions, Sorrento Therapeutics/MabTech, and Sunshine Guojian Pharmaceutical.

The global biosimilar interleukins market is expected to grow from $1.03 billion in 2020 to $1.33 billion in 2021 at a compound annual growth rate (CAGR) of 29.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $4.94 billion in 2025 at a CAGR of 39%.

The biosimilar interleukins market consists of sales of interleukin biosimilars generated by the establishments that manufacture interleukin biosimilars that are used to treat various autoimmune diseases. Interleukin is a substance derived from white blood cells that enhances infection activity and is used to fight certain types of cancer.

The biosimilar interleukins market covered in this report is segmented by type into IL-17, IL-23, IL-1, IL-5, IL-6, others. It is also segmented by application into psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease (IBD), others and by distribution channel into hospital pharmacies, online pharmacies, retail pharmacies, clinics, research institutes.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The regulatory framework around the approval of interleukin biosimilars hampers the growth of the market. Biosimilars are manufactured with changes in the manufacturing process impacting the physicochemical and functional properties of a biologic drug and it is impractical to create an exact copy of the biologic drug. This compels the manufacturers to demonstrate biosimilarity between interleukin biosimilar and the biologic drug to prove that there are no clinically meaningful differences. This calls for extensive comparative analytical, nonclinical, and clinical assessments to get approval from the medical authorities, thereby, increasing the cost of the approval process and restraining the growth of the market.

In January 2020, Sanofi, a France-based pharmaceutical company, acquired Synthorx, Inc. for $2.5 billion. This acquisition enhances Sanofi’s position as an emerging leader in the area of oncology and immunology. Synthorx, Inc. is a US-based biotechnology company focused on developing interleukins for people suffering from cancer and autoimmune disorders.

The increasing prevalence of autoimmune diseases such as psoriasis and rheumatoid arthritis is expected to boost the growth of the interleukin biosimilars market in the forecast period. Autoimmune disorders are conditions in which the immune cells cannot distinguish healthy cells from potentially dangerous antibodies. Biologic drugs such as anti-interleukin antibodies have shown significant clinical benefit in regulating the cells, and in directing proliferation, activation, and migration of the cells. According to the British Society for Immunology report 2018, many autoimmune disorders showed a year-on-year increase in incidence at rates between 3% and 9%. In the US, there were 7.4 million people affected with psoriasis in 2017 and this number is ever increasing. Therefore, the increasing prevalence of autoimmune diseases is increasing the demand for the biosimilar interleukins market and is expected to drive the growth of the market.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • MabPharm
  • Gedeon Richter
  • Bio-Thera Solutions
  • Sorrento Therapeutics/MabTech
  • Sunshine Guojian Pharmaceutical
Note: Product cover images may vary from those shown

Loading
LOADING...